Literature DB >> 11850272

Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.

Anthony D Harris1, Eli Perencevich, Mary-Claire Roghmann, Glenn Morris, Keith S Kaye, Judith A Johnson.   

Abstract

Antimicrobial resistance is an emerging problem with Pseudomonas aeruginosa. This study determined risk factors for the recovery of piperacillin-tazobactam-resistant P. aeruginosa from clinical cultures from hospitalized patients. A case-control study design was used to compare two groups of case patients with control patients. The first group of case patients was defined by nosocomial isolation of piperacillin-tazobactam-resistant P. aeruginosa, and the second group of cases yielded piperacillin-tazobactam-susceptible P. aeruginosa. Controls were selected in a 6:1 ratio from the same medical or surgical services among which piperacillin-tazobactam-resistant P. aeruginosa arose in patients. Risk factors analyzed included antimicrobial drug exposure, comorbid conditions, and demographics. Bivariate and multivariable analyses were performed. Piperacillin-tazobactam-resistant P. aeruginosa was isolated from 179 patients, and piperacillin-tazobactam-susceptible P. aeruginosa was isolated from 624 patients over a 2.5-year period. Piperacillin-tazobactam (odds ratio [OR] = 6.82; 95% confidence interval [CI], 4.56 to 10.21), imipenem (OR = 2.42; 95% CI, 1.19 to 4.94), aminoglycosides (OR = 2.18; 95% CI, 1.44 to 3.28), vancomycin (OR = 1.87; 95% CI, 1.21 to 2.89), and broad-spectrum cephalosporins (OR = 2.38; 95% CI, 1.45 to 3.88) were the antibiotics associated with the isolation of piperacillin-tazobactam-resistant P. aeruginosa. Exposure to vancomycin (OR = 1.53; 95% CI, 1.13 to 2.06) or ampicillin-sulbactam (OR = 2.28; 95% CI, 1.62 to 3.21) was associated with recovery of piperacillin-tazobactam-susceptible P. aeruginosa. In this study, antibiotics associated with piperacillin-tazobactam-susceptible P. aeruginosa were different from antibiotics associated with piperacillin-tazobactam-resistant P. aeruginosa. Piperacillin-tazobactam was a strong risk factor for piperacillin-tazobactam-resistant P. aeruginosa. Our results suggest that the nosocomial isolation of piperacillin-tazobactam-resistant P. aeruginosa may be affected by multiple antibiotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850272      PMCID: PMC127481          DOI: 10.1128/AAC.46.3.854-858.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review.

Authors:  A D Harris; T B Karchmer; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-03-21       Impact factor: 9.079

Review 2.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

3.  Penicillin-binding proteins and induction of AmpC beta-lactamase.

Authors:  C C Sanders; P A Bradford; A F Ehrhardt; K Bush; K D Young; T A Henderson; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes.

Authors:  G M Lucas; N Lechtzin; D W Puryear; L L Yau; C W Flexner; R D Moore
Journal:  Clin Infect Dis       Date:  1998-05       Impact factor: 9.079

5.  Vancomycin-resistant enterococci in intensive care units: high frequency of stool carriage during a non-outbreak period.

Authors:  B E Ostrowsky; L Venkataraman; E M D'Agata; H S Gold; P C DeGirolami; M H Samore
Journal:  Arch Intern Med       Date:  1999-07-12

6.  Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans.

Authors:  A D Harris; J Castro; D C Sheppard; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

7.  Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients.

Authors:  K S Kaye; A D Harris; H Gold; Y Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed.

Authors:  B Olson; R A Weinstein; C Nathan; W Chamberlin; S A Kabins
Journal:  J Infect Dis       Date:  1984-12       Impact factor: 5.226

9.  Resistance to imipenem among selected gram-negative bacilli in the United States.

Authors:  R P Gaynes; D H Culver
Journal:  Infect Control Hosp Epidemiol       Date:  1992-01       Impact factor: 3.254

Review 10.  Epidemiology of infections due to Pseudomonas aeruginosa.

Authors:  A J Morrison; R P Wenzel
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct
View more
  25 in total

1.  Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.

Authors:  Fekade Bruck Sime; Michael S Roberts; Morgyn S Warner; Uwe Hahn; Thomas A Robertson; Sue Yeend; Andy Phay; Sheila Lehman; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors:  Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study.

Authors:  V G Alexiou; A Michalopoulos; G C Makris; G Peppas; G Samonis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-28       Impact factor: 3.267

Review 4.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

5.  Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

Authors:  Brian D VanScoy; Rodrigo E Mendes; Mariana Castanheira; Jennifer McCauley; Sujata M Bhavnani; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

6.  Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia.

Authors:  Regina B Osih; Jessina C McGregor; Shayna E Rich; Anita C Moore; Jon P Furuno; Eli N Perencevich; Anthony D Harris
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

7.  Time series analysis as a tool to predict the impact of antimicrobial restriction in antibiotic stewardship programs using the example of multidrug-resistant Pseudomonas aeruginosa.

Authors:  Matthias Willmann; Matthias Marschal; Florian Hölzl; Klaus Schröppel; Ingo B Autenrieth; Silke Peter
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

9.  Emergence and prevention measures for multidrug resistant Pseudomonas aeruginosa in catheter-associated urinary tract infection in spinal cord injury patients.

Authors:  K Shigemura; R Takase; K Osawa; K Takaba; M Nomi; M Fujisawa; S Arakawa
Journal:  Spinal Cord       Date:  2014-09-02       Impact factor: 2.772

10.  Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.

Authors:  José A Martínez; Esther Delgado; Sara Martí; Francesc Marco; Jordi Vila; Josep Mensa; Antoni Torres; Carles Codina; Antoni Trilla; Alex Soriano; Aitor Alquezar; Pedro Castro; José M Nicolás
Journal:  Intensive Care Med       Date:  2008-10-21       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.